US Pharma MarketingCrystalys banks $130m to progress gout drug, plan for commercial readiness
Crystalys banks $130m to progress gout drug, plan for commercial readiness is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for its gout drug, dotinurad.
Source: Pharmaceutical Technology